Cardiovascular safety of albiglutide in the Harmony programme: A meta-analysis

The Lancet Diabetes and Endocrinology

Volumn 3, Issue 9, 2015, Pages 697-703

  Fisher, Miles ^a   Petrie, Mark C ^b   Ambery, Philip D ^c   Donaldson, Jill ^d   McMurray, John J V ^b   Ye, June ^e  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; GLIMEPIRIDE; INSULIN GLARGINE; INSULIN LISPRO; LIRAGLUTIDE; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; GLUCAGON LIKE PEPTIDE 1; INCRETIN; RGLP-1 PROTEIN;

ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; EPIDURAL HEMATOMA; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FLUTTER; HEART DEATH; HEART FAILURE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SILENT MYOCARDIAL INFARCTION; SUBDURAL HEMATOMA; THORAX PAIN; UNITED STATES; UNSTABLE ANGINA PECTORIS; AGED; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84940747146     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00233-8     Document Type: Article

References (31)

1. Drucker DJ, Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
2. Scheen AJ, Radermecker RP Addition of incretin therapy to metformin in type 2 diabetes. Lancet 2010, 375:1410-1412.
3. Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes US Department of Health and Human Services, Food and Drug AdministrationFood and Drug Administration, Center for Drug Evaluation and ResearchCenter for Drug Evaluation and Research, (accessed Sept 2, 2014). http://www.fda.gov/downloads/Drugs/GuidanceCompliance%20Regulatory%20Information/Guidances/UCM071627.pdf.
4. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus European Medicines Agency: Committee for Medicinal Products for Human Use, (accessed Sept 2, 2014). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf.
5. Reusch J, Stewart MW, Perkins CM, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes Obese Metab 2014, 16:1257-1264.
6. Nauck M, Stewart M, Perkins C, et al. Harmony 2 results at week 52 primary endpoint: once-weekly albiglutide monotherapy for patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia 2013, 56(suppl 1):S360-S361.
7. Ahren B, Johnson SL, Stewart M, et al. HARMONY 3: 104-week randomized, double blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitaglitin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care 2014, 37:2141-2148. for the HARMONY 3 study group.
8. Weissman PN, Carr MC, Ye J, et al. HARMONY 4: randomised clinical trial comparing once weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia 2014, 57:2457-2484.
9. Home P, Shamanna P, Stewart M, et al. Efficacy and tolerability of albiglutide versus placebo and versus pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes Obese Metab 2015, 17:179-187.
10. Rosenstock J, Fonseca VA, Gross JL, et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice daily prandial insulin. Diabetes Care 2014, 37:2317-2325.
11. Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014, 2:289-297. for the HARMONY 7 study group.
12. Leiter LA, Carr MC, Stewart M, et al. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment; a randomized phase III study. Diabetes Care 2014, 37:2723-2730.
13. Seino Y, Inagaki N, Miyahara H, et al. A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus. Curr Med ResOpin 2014, 30:1095-1106.
14. Summary of product characteristics (Eperzan) GlaxoSmithKline, (accessed Dec 24, 2014). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002735/WC500165119.pdf.
15. Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011, 10:22.
16. Marso SP, Lindsey JB, Stolker JM, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res 2011, 8:237-240.
17. Marso SP, Poulter NR, Nissen SE, et al. Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcomes results (LEADER) trial. Am Heart J 2013, 166:823-830.
18. Sanofi provides an update on lixisenatide new drug application in U.S. Sanofi, (accessed May 25, 2015). http://en.sanofi.com/Images/33756_20130912_lixisenatide_en.pdf.
19. Sanofi announces top-line results for cardiovascular outcomes study of Lyxumia® (lixisenatide) Sanofi, (accessed July 31, 2015). http://en.sanofi.com/NasdaQ_OMX/local/press_releases/sanofi_announces_topline_resul_1904474_19-03-2015!07_00_00.aspx.
20. First CVD outcome trial of a GLP-1 agonist finds no cardiac risk or benefit American Diabetes Association, (accessed July 31, 2015). http://www.diabetes.org/newsroom/press-releases/2015/elixa.html?referrer=https://www.google.co.uk/#sthash.9lVVaHS8.dpuf.
21. Sivertsen J, Rosenmeier J, Holst JJ, Vilsbøll T The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol 2012, 9:209-222.
22. Meier JJ GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012, 8:728-742.
23. Cook S, Togni M, Schaub MC, Wenaweser P, Hess OM High heart rate: a cardiovascular risk factor?. Eur Heart J 2006, 27:2387-2393.
24. Holman RR, Sourij H, Califf RM Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014, 383:2008-2017.
25. Engel SS, Golm GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol 2013, 12:3.
26. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010, 122:16-27.
27. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012, 11:3.
28. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013, 369:1317-1326. SAVOR-TIMI 53 Steering Committee and Investigators.
29. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013, 369:1327-1335. EXAMINE Investigators.
30. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015, 373:232-242. TECOS Study Group.
31. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2014, 2:843-851.